TRPV1 antagonists that cause hypothermia, instead of hyperthermia, in rodents: Compounds’ pharmacological profiles, in vivo targets, thermoeffectors recruited and implications for drug development

A. Garami, E. Pakai, H. A. McDonald, R. M. Reilly, A. Gomtsyan, J. J. Corrigan, E. Pintér, D. X.D. Zhu, S. G. Lehto, N. R. Gavva, P. R. Kym, A. A. Romanovsky

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Aim: Thermoregulatory side effects hinder the development of transient receptor potential vanilloid-1 (TRPV1) antagonists as new painkillers. While many antagonists cause hyperthermia, a well-studied effect, some cause hypothermia. The mechanisms of this hypothermia are unknown and were studied herein. Methods: Two hypothermia-inducing TRPV1 antagonists, the newly synthesized A-1165901 and the known AMG7905, were used in physiological experiments in rats and mice. Their pharmacological profiles against rat TRPV1 were studied in vitro. Results: Administered peripherally, A-1165901 caused hypothermia in rats by either triggering tail-skin vasodilation (at thermoneutrality) or inhibiting thermogenesis (in the cold). A-1165901-induced hypothermia did not occur in rats with desensitized (by an intraperitoneal dose of the TRPV1 agonist resiniferatoxin) sensory abdominal nerves. The hypothermic responses to A-1165901 and AMG7905 (administered intragastrically or intraperitoneally) were absent in Trpv1−/− mice, even though both compounds evoked pronounced hypothermia in Trpv1+/+ mice. In vitro, both A-1165901 and AMG7905 potently potentiated TRPV1 activation by protons, while potently blocking channel activation by capsaicin. Conclusion: TRPV1 antagonists cause hypothermia by an on-target action: on TRPV1 channels on abdominal sensory nerves. These channels are tonically activated by protons and drive the reflectory inhibition of thermogenesis and tail-skin vasoconstriction. Those TRPV1 antagonists that cause hypothermia further inhibit these cold defences, thus decreasing body temperature. Significance: TRPV1 antagonists (of capsaicin activation) are highly unusual in that they can cause both hyper- and hypothermia by modulating the same mechanism. For drug development, this means that both side effects can be dealt with simultaneously, by minimizing these compounds’ interference with TRPV1 activation by protons.

Original languageEnglish
Article numbere13038
JournalActa Physiologica
Volume223
Issue number3
DOIs
Publication statusPublished - Jul 1 2018

Fingerprint

Hypothermia
Rodentia
Fever
Pharmacology
Pharmaceutical Preparations
Protons
Thermogenesis
Capsaicin
Tail
vanilloid receptor subtype 1
Induced Hypothermia
Skin
Vasoconstriction
Body Temperature
Vasodilation

Keywords

  • hyperthermia
  • hypothermia
  • protons
  • thermoregulation
  • TRPV1 antagonists
  • vanilloids

ASJC Scopus subject areas

  • Physiology

Cite this

TRPV1 antagonists that cause hypothermia, instead of hyperthermia, in rodents : Compounds’ pharmacological profiles, in vivo targets, thermoeffectors recruited and implications for drug development. / Garami, A.; Pakai, E.; McDonald, H. A.; Reilly, R. M.; Gomtsyan, A.; Corrigan, J. J.; Pintér, E.; Zhu, D. X.D.; Lehto, S. G.; Gavva, N. R.; Kym, P. R.; Romanovsky, A. A.

In: Acta Physiologica, Vol. 223, No. 3, e13038, 01.07.2018.

Research output: Contribution to journalArticle

Garami, A. ; Pakai, E. ; McDonald, H. A. ; Reilly, R. M. ; Gomtsyan, A. ; Corrigan, J. J. ; Pintér, E. ; Zhu, D. X.D. ; Lehto, S. G. ; Gavva, N. R. ; Kym, P. R. ; Romanovsky, A. A. / TRPV1 antagonists that cause hypothermia, instead of hyperthermia, in rodents : Compounds’ pharmacological profiles, in vivo targets, thermoeffectors recruited and implications for drug development. In: Acta Physiologica. 2018 ; Vol. 223, No. 3.
@article{201b84dfee8d409f8c7d5ad86283b40d,
title = "TRPV1 antagonists that cause hypothermia, instead of hyperthermia, in rodents: Compounds’ pharmacological profiles, in vivo targets, thermoeffectors recruited and implications for drug development",
abstract = "Aim: Thermoregulatory side effects hinder the development of transient receptor potential vanilloid-1 (TRPV1) antagonists as new painkillers. While many antagonists cause hyperthermia, a well-studied effect, some cause hypothermia. The mechanisms of this hypothermia are unknown and were studied herein. Methods: Two hypothermia-inducing TRPV1 antagonists, the newly synthesized A-1165901 and the known AMG7905, were used in physiological experiments in rats and mice. Their pharmacological profiles against rat TRPV1 were studied in vitro. Results: Administered peripherally, A-1165901 caused hypothermia in rats by either triggering tail-skin vasodilation (at thermoneutrality) or inhibiting thermogenesis (in the cold). A-1165901-induced hypothermia did not occur in rats with desensitized (by an intraperitoneal dose of the TRPV1 agonist resiniferatoxin) sensory abdominal nerves. The hypothermic responses to A-1165901 and AMG7905 (administered intragastrically or intraperitoneally) were absent in Trpv1−/− mice, even though both compounds evoked pronounced hypothermia in Trpv1+/+ mice. In vitro, both A-1165901 and AMG7905 potently potentiated TRPV1 activation by protons, while potently blocking channel activation by capsaicin. Conclusion: TRPV1 antagonists cause hypothermia by an on-target action: on TRPV1 channels on abdominal sensory nerves. These channels are tonically activated by protons and drive the reflectory inhibition of thermogenesis and tail-skin vasoconstriction. Those TRPV1 antagonists that cause hypothermia further inhibit these cold defences, thus decreasing body temperature. Significance: TRPV1 antagonists (of capsaicin activation) are highly unusual in that they can cause both hyper- and hypothermia by modulating the same mechanism. For drug development, this means that both side effects can be dealt with simultaneously, by minimizing these compounds’ interference with TRPV1 activation by protons.",
keywords = "hyperthermia, hypothermia, protons, thermoregulation, TRPV1 antagonists, vanilloids",
author = "A. Garami and E. Pakai and McDonald, {H. A.} and Reilly, {R. M.} and A. Gomtsyan and Corrigan, {J. J.} and E. Pint{\'e}r and Zhu, {D. X.D.} and Lehto, {S. G.} and Gavva, {N. R.} and Kym, {P. R.} and Romanovsky, {A. A.}",
year = "2018",
month = "7",
day = "1",
doi = "10.1111/apha.13038",
language = "English",
volume = "223",
journal = "Skandinavisches Archiv F{\"u}r Physiologie",
issn = "0370-839X",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - TRPV1 antagonists that cause hypothermia, instead of hyperthermia, in rodents

T2 - Compounds’ pharmacological profiles, in vivo targets, thermoeffectors recruited and implications for drug development

AU - Garami, A.

AU - Pakai, E.

AU - McDonald, H. A.

AU - Reilly, R. M.

AU - Gomtsyan, A.

AU - Corrigan, J. J.

AU - Pintér, E.

AU - Zhu, D. X.D.

AU - Lehto, S. G.

AU - Gavva, N. R.

AU - Kym, P. R.

AU - Romanovsky, A. A.

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Aim: Thermoregulatory side effects hinder the development of transient receptor potential vanilloid-1 (TRPV1) antagonists as new painkillers. While many antagonists cause hyperthermia, a well-studied effect, some cause hypothermia. The mechanisms of this hypothermia are unknown and were studied herein. Methods: Two hypothermia-inducing TRPV1 antagonists, the newly synthesized A-1165901 and the known AMG7905, were used in physiological experiments in rats and mice. Their pharmacological profiles against rat TRPV1 were studied in vitro. Results: Administered peripherally, A-1165901 caused hypothermia in rats by either triggering tail-skin vasodilation (at thermoneutrality) or inhibiting thermogenesis (in the cold). A-1165901-induced hypothermia did not occur in rats with desensitized (by an intraperitoneal dose of the TRPV1 agonist resiniferatoxin) sensory abdominal nerves. The hypothermic responses to A-1165901 and AMG7905 (administered intragastrically or intraperitoneally) were absent in Trpv1−/− mice, even though both compounds evoked pronounced hypothermia in Trpv1+/+ mice. In vitro, both A-1165901 and AMG7905 potently potentiated TRPV1 activation by protons, while potently blocking channel activation by capsaicin. Conclusion: TRPV1 antagonists cause hypothermia by an on-target action: on TRPV1 channels on abdominal sensory nerves. These channels are tonically activated by protons and drive the reflectory inhibition of thermogenesis and tail-skin vasoconstriction. Those TRPV1 antagonists that cause hypothermia further inhibit these cold defences, thus decreasing body temperature. Significance: TRPV1 antagonists (of capsaicin activation) are highly unusual in that they can cause both hyper- and hypothermia by modulating the same mechanism. For drug development, this means that both side effects can be dealt with simultaneously, by minimizing these compounds’ interference with TRPV1 activation by protons.

AB - Aim: Thermoregulatory side effects hinder the development of transient receptor potential vanilloid-1 (TRPV1) antagonists as new painkillers. While many antagonists cause hyperthermia, a well-studied effect, some cause hypothermia. The mechanisms of this hypothermia are unknown and were studied herein. Methods: Two hypothermia-inducing TRPV1 antagonists, the newly synthesized A-1165901 and the known AMG7905, were used in physiological experiments in rats and mice. Their pharmacological profiles against rat TRPV1 were studied in vitro. Results: Administered peripherally, A-1165901 caused hypothermia in rats by either triggering tail-skin vasodilation (at thermoneutrality) or inhibiting thermogenesis (in the cold). A-1165901-induced hypothermia did not occur in rats with desensitized (by an intraperitoneal dose of the TRPV1 agonist resiniferatoxin) sensory abdominal nerves. The hypothermic responses to A-1165901 and AMG7905 (administered intragastrically or intraperitoneally) were absent in Trpv1−/− mice, even though both compounds evoked pronounced hypothermia in Trpv1+/+ mice. In vitro, both A-1165901 and AMG7905 potently potentiated TRPV1 activation by protons, while potently blocking channel activation by capsaicin. Conclusion: TRPV1 antagonists cause hypothermia by an on-target action: on TRPV1 channels on abdominal sensory nerves. These channels are tonically activated by protons and drive the reflectory inhibition of thermogenesis and tail-skin vasoconstriction. Those TRPV1 antagonists that cause hypothermia further inhibit these cold defences, thus decreasing body temperature. Significance: TRPV1 antagonists (of capsaicin activation) are highly unusual in that they can cause both hyper- and hypothermia by modulating the same mechanism. For drug development, this means that both side effects can be dealt with simultaneously, by minimizing these compounds’ interference with TRPV1 activation by protons.

KW - hyperthermia

KW - hypothermia

KW - protons

KW - thermoregulation

KW - TRPV1 antagonists

KW - vanilloids

UR - http://www.scopus.com/inward/record.url?scp=85041842697&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041842697&partnerID=8YFLogxK

U2 - 10.1111/apha.13038

DO - 10.1111/apha.13038

M3 - Article

AN - SCOPUS:85041842697

VL - 223

JO - Skandinavisches Archiv Für Physiologie

JF - Skandinavisches Archiv Für Physiologie

SN - 0370-839X

IS - 3

M1 - e13038

ER -